PL2442645T3 - Estry choliny - Google Patents

Estry choliny

Info

Publication number
PL2442645T3
PL2442645T3 PL10790043T PL10790043T PL2442645T3 PL 2442645 T3 PL2442645 T3 PL 2442645T3 PL 10790043 T PL10790043 T PL 10790043T PL 10790043 T PL10790043 T PL 10790043T PL 2442645 T3 PL2442645 T3 PL 2442645T3
Authority
PL
Poland
Prior art keywords
choline esters
choline
esters
Prior art date
Application number
PL10790043T
Other languages
English (en)
Inventor
William Garner
Margaret Garner
George Minno
David Gooden
Original Assignee
Encore Health Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encore Health Llc filed Critical Encore Health Llc
Publication of PL2442645T3 publication Critical patent/PL2442645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D343/00—Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL10790043T 2009-06-15 2010-06-15 Estry choliny PL2442645T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18700509P 2009-06-15 2009-06-15
US22493009P 2009-07-13 2009-07-13
US24223209P 2009-09-14 2009-09-14
EP20100790043 EP2442645B1 (en) 2009-06-15 2010-06-15 Choline esters
PCT/US2010/038642 WO2010147962A1 (en) 2009-06-15 2010-06-15 Choline esters

Publications (1)

Publication Number Publication Date
PL2442645T3 true PL2442645T3 (pl) 2015-02-27

Family

ID=43306962

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10790043T PL2442645T3 (pl) 2009-06-15 2010-06-15 Estry choliny
PL14181820T PL2821405T3 (pl) 2009-06-15 2010-06-15 Estry cholinowe do leczenia prezbiopii i zaćmy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14181820T PL2821405T3 (pl) 2009-06-15 2010-06-15 Estry cholinowe do leczenia prezbiopii i zaćmy

Country Status (8)

Country Link
US (7) US8410162B2 (pl)
EP (2) EP2442645B1 (pl)
DK (2) DK2442645T3 (pl)
ES (2) ES2579173T3 (pl)
HK (1) HK1205122A1 (pl)
PL (2) PL2442645T3 (pl)
PT (2) PT2442645E (pl)
WO (1) WO2010147962A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
PL2442645T3 (pl) 2009-06-15 2015-02-27 Encore Health Llc Estry choliny
ES2640474T3 (es) * 2010-11-18 2017-11-03 Ischemix Llc Compuestos lipoílicos y su uso para el tratamiento de la lesión isquémica
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
US9541773B2 (en) 2012-10-17 2017-01-10 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
BR112016020181A8 (pt) 2014-03-03 2021-06-29 Encore Vision Inc composições de ácido lipoico éster colina e métodos de uso.
US10449209B2 (en) 2015-04-29 2019-10-22 Arterez, Llc Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
EP3352739B1 (en) * 2015-09-24 2021-10-27 Novartis AG Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
ES2952834T3 (es) 2017-04-25 2023-11-06 Ischemix Llc Lipoil-Glu-Ala para el tratamiento de daño neurodegenerativo producido por traumatismo craneoencefálico
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
WO2019150341A1 (en) * 2018-02-05 2019-08-08 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
CN113710320A (zh) * 2019-04-17 2021-11-26 参天制药株式会社 硫辛酸前药
CA3170063A1 (en) * 2020-02-05 2021-08-12 Vtv Therapeutics Llc Substituted fused imidazole derivatives and methods of treating refractive ocular disorders
CN113387923A (zh) 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
TW202210066A (zh) * 2020-05-26 2022-03-16 日商參天製藥股份有限公司 對老花眼之治療或預防有用之含硫化合物
EP4232157A4 (en) * 2020-10-22 2024-08-28 Xequel Bio Inc PEPTIDE FORMULATIONS AND THEIR OPHTHALMIC USE
KR102595126B1 (ko) * 2022-09-27 2023-10-30 하나제약 주식회사 콜린알포세레이트 에스테르 유도체의 제조방법과 그 용도

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935962A (en) 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3855240A (en) 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
WO1993002639A1 (en) 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1993025166A1 (en) 1992-06-10 1993-12-23 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
EP0648118A1 (en) 1992-07-02 1995-04-19 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0649532B1 (en) 1992-07-06 1997-11-12 Biomira, Inc. Photoactivation of proteins for conjugation purposes
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
US5465737A (en) 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
DK0653926T3 (da) 1992-08-07 1999-11-01 Keravision Inc Intrastromal cornealring
DE4345199C2 (de) 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
AU704591B2 (en) 1994-04-04 1999-04-29 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US6007510A (en) * 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
US5843184A (en) 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) * 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
AU758903B2 (en) * 1998-11-26 2003-04-03 Pentapharm Ag Transport system conjugate
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US7977385B2 (en) * 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EP1307442A2 (de) 2000-08-02 2003-05-07 Basf Aktiengesellschaft Verfahren zur herstellung von liponsäure und dihydroliponsäure
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
WO2002013863A2 (en) 2000-08-16 2002-02-21 Refocus, Llc. Presbyopia treatment by lens alteration
US6923955B2 (en) 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
US20050112113A1 (en) 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8147816B2 (en) 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
DE10045059A1 (de) 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
FR2815541B1 (fr) * 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
CA2435374A1 (en) 2001-01-19 2002-07-25 Newlens, Llc Presbyopia treatment by reducing and preventing lenticular disulfide crosslinks
WO2002076935A1 (fr) 2001-03-19 2002-10-03 Senju Pharmaceutical Co., Ltd. Nouveau derive de l'acide lipoique et son utilisation
JP2005515156A (ja) * 2001-05-25 2005-05-26 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するための単一アミノ酸に基づく化合物
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
WO2003084532A1 (en) 2002-04-03 2003-10-16 Avery Mitchell A Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
AU2003264412A1 (en) * 2002-09-13 2004-04-30 Oga Research, Incorporated Melanin extinguisher
JP2006504701A (ja) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
CA2547086A1 (en) * 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
CA2615360A1 (en) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US20070055070A1 (en) 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
US7973073B2 (en) 2006-06-16 2011-07-05 Indigene Pharmaceuticals, Inc. Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
EP2131679B1 (en) * 2007-02-22 2019-03-27 Children's Hospital & Research Center at Oakland Fatty acid formulations and methods of use thereof
JP2010520333A (ja) 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
UA86441C2 (ru) * 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
PL2442645T3 (pl) 2009-06-15 2015-02-27 Encore Health Llc Estry choliny

Also Published As

Publication number Publication date
WO2010147962A1 (en) 2010-12-23
ES2524706T3 (es) 2014-12-11
EP2442645A1 (en) 2012-04-25
DK2821405T3 (en) 2016-07-25
US8410162B2 (en) 2013-04-02
US9326970B2 (en) 2016-05-03
US20200352903A1 (en) 2020-11-12
EP2821405B1 (en) 2016-04-13
PT2821405E (pt) 2016-06-14
US20180228767A1 (en) 2018-08-16
DK2442645T3 (en) 2014-11-24
EP2442645A4 (en) 2013-03-06
HK1205122A1 (zh) 2015-12-11
EP2821405A1 (en) 2015-01-07
US20140121266A1 (en) 2014-05-01
US20160287557A1 (en) 2016-10-06
ES2579173T3 (es) 2016-08-05
US20100317725A1 (en) 2010-12-16
PL2821405T3 (pl) 2017-08-31
US20220151988A1 (en) 2022-05-19
EP2442645B1 (en) 2014-08-27
PT2442645E (pt) 2014-11-05
US20150111959A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
PL2442645T3 (pl) Estry choliny
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
EP2462514A4 (en) GREEN BOOKS
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
AU327392S (en) Tray
EP2519921A4 (en) CALL TRACING
DK2464943T3 (en) Systemintegration
GB201011356D0 (en) Ventalation arrangements
GB0917672D0 (en) Tray
GB0916454D0 (en) Growbag tray
EP2531028A4 (en) TOCOTRIENOL ESTERS
GB2461327B (en) Tray
AU331830S (en) Tray
EP2510125A4 (en) HYPER PRIMER
AU4240P (en) Tuckerbox xTriticosecale
AU4926P (en) Bonscalib Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
GB0921748D0 (en) Switch-actuated arrangements
GB0915611D0 (en) Ilight
GB0903349D0 (en) Concept four
AU327323S (en) Tray
AU327317S (en) Tray
GB0911301D0 (en) Tray